share_log

Aura Biosciences Up 22%, Insider Buyers Are Up 24%

Aura Biosciences Up 22%, Insider Buyers Are Up 24%

Aura Biosciences上漲22%,內部買家達到24%
Simply Wall St ·  09/11 19:11

Aura Biosciences, Inc. (NASDAQ:AURA) insiders who bought shares over the past year were rewarded handsomely last week. The stock rose 22%, resulting in a US$81m rise in the company's market capitalisation, translating to a gain of 24% on their initial investment. As a result, their original purchase of US$1.60m worth of stock is now worth US$1.98m.

過去一年裏購買Aura Biosciences, Inc. (NASDAQ:AURA)股票的內部人士上週收穫豐厚。股票上漲了22%,導致公司市值上升了8100萬美元,相當於其最初投資的24%。因此,他們最初購買的160萬美元股票現在價值198萬美元。

While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.

雖然在長期投資中,內部交易並不是最重要的事情,但我們認爲關注內部人士的行動是非常合理的。

The Last 12 Months Of Insider Transactions At Aura Biosciences

在Aura Biosciences的最近12個月的內部交易中,獨立董事會主席大衛·約翰遜進行了最大的內部購買。這次交易的金額是每股7.30美元的140萬美元股票。即使購買價格顯著低於最近的價格(9.02美元),我們仍認爲內部購買是積極的。因爲它發生在一個較低的估值上,這並不告訴我們內部人士是否認爲今天的價格具有吸引力。

The Independent Chairman of the Board David Johnson made the biggest insider purchase in the last 12 months. That single transaction was for US$1.4m worth of shares at a price of US$7.30 each. Even though the purchase was made at a significantly lower price than the recent price (US$9.02), we still think insider buying is a positive. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.

大衛·約翰遜在過去12個月裏以平均每股7.30美元的價格購買了21.967萬股。您可以在下面看到過去12個月內部交易的視覺展示。如果您點擊圖表,可以看到所有的個別交易,包括股價、個人和日期!

David Johnson bought 219.67k shares over the last 12 months at an average price of US$7.30. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

大衛·約翰遜在過去12個月裏以平均每股7.30美元的價格購買了21.967萬股。您可以在下面看到過去12個月內部交易的視覺展示。如果您點擊圖表,可以看到所有的個別交易,包括股價、個人和日期!

big
NasdaqGM:AURA Insider Trading Volume September 11th 2024
納斯達克主板:AURA內幕交易量2024年9月11日

Aura Biosciences is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

AURA生物科技並不是唯一一家內部人士正在購買的股票。所以請查看這個免費的內部交易買入名單。

Does Aura Biosciences Boast High Insider Ownership?

AURA生物科技是否擁有高內部持股?

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Our data suggests Aura Biosciences insiders own 1.2% of the company, worth about US$4.7m. We prefer to see high levels of insider ownership.

評估公司領導人與其他股東的利益是否一致的另一種方法是查看他們所持有的股份數量。通常來說,內部人持股越高,他們越有動力爲公司長期發展而努力。我們的數據顯示,AURA生物科技內部人持有公司的1.2%股份,價值約470萬美元。我們更喜歡看到高水平的內部持股。

So What Do The Aura Biosciences Insider Transactions Indicate?

那麼AURA生物科技的內部交易意味着什麼?

There haven't been any insider transactions in the last three months -- that doesn't mean much. However, our analysis of transactions over the last year is heartening. While we have no worries about the insider transactions, we'd be more comfortable if they owned more Aura Biosciences stock. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Aura Biosciences. Our analysis shows 4 warning signs for Aura Biosciences (2 are concerning!) and we strongly recommend you look at these before investing.

過去三個月內沒有任何內部交易,但這並不意味着太多。然而,我們對過去一年的交易分析是鼓舞人心的。雖然我們對內部交易沒有什麼擔憂,但如果他們持有更多AURA生物科技股票會更讓人感到舒適。除了了解正在進行的內部交易外,識別AURA生物科技面臨的風險也是有益的。我們的分析顯示AURA生物科技有4個警告信號(其中2個令人關注!),我們強烈建議您在投資之前查看這些。

Of course Aura Biosciences may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

當然,Aura Biosciences可能不是最好的股票購買選擇。因此,您可能希望查看這個高質量公司的免費合集。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論